BidaskClub downgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a sell rating to a strong sell rating in a research report report published on Thursday.
A number of other equities research analysts have also recently weighed in on LXRX. Needham & Company LLC reaffirmed a hold rating on shares of Lexicon Pharmaceuticals in a report on Monday, July 30th. Wedbush reaffirmed a buy rating and set a $42.00 price target on shares of Lexicon Pharmaceuticals in a report on Monday, June 18th. Zacks Investment Research raised Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Friday, August 3rd. Stifel Nicolaus reaffirmed a buy rating and set a $23.00 price target (down previously from $24.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, July 31st. Finally, ValuEngine cut Lexicon Pharmaceuticals from a hold rating to a sell rating in a report on Friday, August 17th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. Lexicon Pharmaceuticals currently has a consensus rating of Hold and a consensus target price of $25.50.
Shares of NASDAQ LXRX opened at $9.48 on Thursday. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -7.46 and a beta of 0.35. The company has a current ratio of 2.71, a quick ratio of 2.68 and a debt-to-equity ratio of -45.80. Lexicon Pharmaceuticals has a 52-week low of $7.67 and a 52-week high of $13.97.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Monday, July 30th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.02. The company had revenue of $13.75 million for the quarter, compared to analysts’ expectations of $15.88 million. Lexicon Pharmaceuticals had a negative return on equity of 369.13% and a negative net margin of 137.32%. The business’s revenue for the quarter was up 14.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.33) earnings per share. As a group, analysts anticipate that Lexicon Pharmaceuticals will post -1.38 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in LXRX. BlackRock Inc. raised its holdings in Lexicon Pharmaceuticals by 4.6% during the second quarter. BlackRock Inc. now owns 4,422,293 shares of the biopharmaceutical company’s stock worth $53,066,000 after purchasing an additional 195,461 shares in the last quarter. Price Capital Management Inc. bought a new stake in Lexicon Pharmaceuticals during the second quarter worth approximately $1,352,000. UBS Group AG raised its holdings in Lexicon Pharmaceuticals by 94.5% during the first quarter. UBS Group AG now owns 218,923 shares of the biopharmaceutical company’s stock worth $1,876,000 after purchasing an additional 106,392 shares in the last quarter. A.R.T. Advisors LLC raised its holdings in Lexicon Pharmaceuticals by 71.0% during the first quarter. A.R.T. Advisors LLC now owns 54,266 shares of the biopharmaceutical company’s stock worth $465,000 after purchasing an additional 22,533 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Lexicon Pharmaceuticals during the second quarter worth approximately $205,000.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
See Also: What is a Call Option?
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.